Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Cancer Biomarker: Current Status and Future Perspectives
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Cancer Biomarker: Current Status and Future Perspectives

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 15 September 2024 | Viewed by 11416

Special Issue Editors

Dr. Susan Costantini

E-Mail Website
Guest Editor
Experimental Pharmacology, Istituto Nazionale Tumori—IRCCS—Fondazione G. Pascale, 80131 Naples, Italy
Interests: cancer; cytokines; metabolome; NMR; systems biology; computational biology; molecular biology
Special Issues, Collections and Topics in MDPI journals
Dr. Francesca Capone

E-Mail Website
Guest Editor
Experimental Pharmacology, Istituto Nazionale Tumori—IRCCS—Fondazione G. Pascale, 80131 Naples, Italy
Interests: cancer biomarker

Special Issue Information

Dear Colleagues,

In recent years, omics technologies have led to the identification of numerous biomarkers based on DNA, RNA, miRNA, long non-coding RNA, protein, and metabolic and lipidic alterations that may be combined with clinical pathological data to greatly predict cancer progression, patient outcome, cancer recurrence, and therapeutic treatment responses.

To date, only a few cancer biomarkers have entered into clinical practice. However, the search for new prognostic and predictive biomarkers is the object of many studies performed on cells, blood samples, and tissues. In this context, so-called “liquid biopsies” allow a snapshot of a patient’s pathophysiological state at a given time and provide dynamic monitoring with insight into the spatial and temporal clonal evolution processes of the tumor, including secondary resistance to treatment, which is prohibited by the invasiveness of tissue biopsies.

The aim of this Special Issue is to present the latest research on the identification of new genetic, epigenetic, miRNA, protein, metabolic, and lipidic cancer biomarkers, and their combination and integration by bioinformatics and systems biology approaches.

Dr. Susan Costantini
Dr. Francesca Capone
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • cytokines/chemokines
  • proteins
  • miRNAs
  • metabolites
  • lipids
  • extracellular vesicles
  • cell biology/tissue
  • liquid biopsy
  • systems biology

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

16 pages, 2053 KiB  
Article
Quantitative Proteomic Analysis of MCM3 in ThinPrep Samples of Patients with Cervical Preinvasive Cancer
by Büşra Köse, Ralf van de Laar, Heleen van Beekhuizen, Folkert van Kemenade, Ahmet Tarik Baykal, Theo Luider and Coşkun Güzel
Int. J. Mol. Sci. 2023, 24(13), 10473; https://doi.org/10.3390/ijms241310473 - 21 Jun 2023
Viewed by 1411
Abstract
Triage methods for cervical cancer detection show moderate accuracy and present considerable false-negative and false-positive result rates. A complementary diagnostic parameter could help improve the accuracy of identifying patients who need treatment. A pilot study was performed using a targeted proteomics approach with [...] Read more.
Triage methods for cervical cancer detection show moderate accuracy and present considerable false-negative and false-positive result rates. A complementary diagnostic parameter could help improve the accuracy of identifying patients who need treatment. A pilot study was performed using a targeted proteomics approach with opportunistic ThinPrep samples obtained from women collected at the hospital’s outpatient clinic to determine the concentration levels of minichromosome maintenance-3 (MCM3) and envoplakin (EVPL) proteins. Forty samples with ‘negative for intraepithelial lesion or malignancy’ (NILM), 21 samples with ‘atypical squamous cells of undetermined significance’ (ASC-US), and 33 samples with ‘low-grade squamous intraepithelial lesion and worse’ (≥LSIL) were analyzed, using cytology and the patients’ histology reports. Highly accurate concordance was obtained for gold-standard-confirmed samples, demonstrating that the MCM3/EVPL ratio can discriminate between non-dysplastic and dysplastic samples. On that account, we propose that MCM3 and EVPL are promising candidate protein biomarkers for population-based cervical cancer screening. Full article
(This article belongs to the Special Issue Cancer Biomarker: Current Status and Future Perspectives)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

29 pages, 3195 KiB  
Review
Non-Genomic Hallmarks of Aging—The Review
by Drahomira Holmannova, Pavel Borsky, Helena Parova, Tereza Stverakova, Milan Vosmik, Libor Hruska, Zdenek Fiala and Lenka Borska
Int. J. Mol. Sci. 2023, 24(20), 15468; https://doi.org/10.3390/ijms242015468 - 23 Oct 2023
Cited by 1 | Viewed by 2653
Abstract
Aging is a natural, gradual, and inevitable process associated with a series of changes at the molecular, cellular, and tissue levels that can lead to an increased risk of many diseases, including cancer. The most significant changes at the genomic level (DNA damage, [...] Read more.
Aging is a natural, gradual, and inevitable process associated with a series of changes at the molecular, cellular, and tissue levels that can lead to an increased risk of many diseases, including cancer. The most significant changes at the genomic level (DNA damage, telomere shortening, epigenetic changes) and non-genomic changes are referred to as hallmarks of aging. The hallmarks of aging and cancer are intertwined. Many studies have focused on genomic hallmarks, but non-genomic hallmarks are also important and may additionally cause genomic damage and increase the expression of genomic hallmarks. Understanding the non-genomic hallmarks of aging and cancer, and how they are intertwined, may lead to the development of approaches that could influence these hallmarks and thus function not only to slow aging but also to prevent cancer. In this review, we focus on non-genomic changes. We discuss cell senescence, disruption of proteostasis, deregualation of nutrient sensing, dysregulation of immune system function, intercellular communication, mitochondrial dysfunction, stem cell exhaustion and dysbiosis. Full article
(This article belongs to the Special Issue Cancer Biomarker: Current Status and Future Perspectives)
►▼ Show Figures

Figure 1

20 pages, 1474 KiB  
Review
The Role of Cocaine- and Amphetamine-Regulated Transcript (CART) in Cancer: A Systematic Review
by Maja Owe-Larsson, Jan Pawłasek, Tomasz Piecha, Alicja Sztokfisz-Ignasiak, Mikołaj Pater and Izabela R. Janiuk
Int. J. Mol. Sci. 2023, 24(12), 9986; https://doi.org/10.3390/ijms24129986 - 10 Jun 2023
Cited by 3 | Viewed by 2009
Abstract
The functions of cocaine- and amphetamine-regulated transcript (CART) neuropeptide encoded by the CARTPT gene vary from modifying behavior and pain sensitivity to being an antioxidant. Putative CART peptide receptor GPR160 was implicated recently in the pathogenesis of cancer. However, the exact role of [...] Read more.
The functions of cocaine- and amphetamine-regulated transcript (CART) neuropeptide encoded by the CARTPT gene vary from modifying behavior and pain sensitivity to being an antioxidant. Putative CART peptide receptor GPR160 was implicated recently in the pathogenesis of cancer. However, the exact role of CART protein in the development of neoplasms remains unclear. This systematic review includes articles retrieved from the Scopus, PubMed, Web of Science and Medline Complete databases. Nineteen publications that met the inclusion criteria and describe the association of CART and cancer were analyzed. CART is expressed in various types of cancer, e.g., in breast cancer and neuroendocrine tumors (NETs). The role of CART as a potential biomarker in breast cancer, stomach adenocarcinoma, glioma and some types of NETs was suggested. In various cancer cell lines, CARTPT acts an oncogene, enhancing cellular survival by the activation of the ERK pathway, the stimulation of other pro-survival molecules, the inhibition of apoptosis or the increase in cyclin D1 levels. In breast cancer, CART was reported to protect tumor cells from tamoxifen-mediated death. Taken together, these data support the role of CART activity in the pathogenesis of cancer, thus opening new diagnostic and therapeutic approaches in neoplastic disorders. Full article
(This article belongs to the Special Issue Cancer Biomarker: Current Status and Future Perspectives)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

9 pages, 898 KiB  
Case Report
Germline Variants in MLH1 and ATM Genes in a Young Patient with MSI-H in a Precancerous Colonic Lesion
by Antonio Nolano, Giovanni Battista Rossi, Valentina D’Angelo, Raffaella Liccardo, Marina De Rosa, Paola Izzo and Francesca Duraturo
Int. J. Mol. Sci. 2023, 24(6), 5970; https://doi.org/10.3390/ijms24065970 - 22 Mar 2023
Viewed by 4728
Abstract
Lynch syndrome (LS) is an autosomal dominant inherited disorder that primarily predisposes individuals to colorectal and endometrial cancer. It is associated with pathogenic variants in DNA mismatch repair (MMR) genes. In this study, we report the case of a 16-year-old boy who developed [...] Read more.
Lynch syndrome (LS) is an autosomal dominant inherited disorder that primarily predisposes individuals to colorectal and endometrial cancer. It is associated with pathogenic variants in DNA mismatch repair (MMR) genes. In this study, we report the case of a 16-year-old boy who developed a precancerous colonic lesion and had a clinical suspicion of LS. The proband was found to have a somatic MSI-H status. Analysis of the coding sequences and flanking introns of the MLH1 and MSH2 genes by Sanger sequencing led to the identification of the variant of uncertain significance, namely, c.589-9_589-6delGTTT in the MLH1 gene. Further investigation revealed that this variant was likely pathogenetic. Subsequent next-generation sequencing panel analysis revealed the presence of two variants of uncertain significance in the ATM gene. We conclude that the phenotype of our index case is likely the result of a synergistic effect of these identified variants. Future studies will allow us to understand how risk alleles in different colorectal-cancer-prone genes interact with each other to increase an individual’s risk of developing cancer. Full article
(This article belongs to the Special Issue Cancer Biomarker: Current Status and Future Perspectives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop